Navigation Links
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
Date:9/9/2008

LAS VEGAS, Sept. 9 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces that its first US site is open for patient enrollment for its Phase II clinical trial for the treatment of severe coronary heart disease. In the coming weeks, CVBT anticipates announcing additional sites as they open for enrollment. For current details about the clinical sites participating in CVBT's Phase II heart trial, please visit http://www.cvbt.com.

In this Phase II trial, CVBT's drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients' hearts, stimulating a healing process called angiogenesis. The drug will be delivered using the NOGA(R) XP Cardiac Navigation system and the MyoStar(TM) injection catheter.

Subjects must be between 25 and 75 years of age with at least a 3 month history of chronic stable angina triggered by physical exertion and must have a Canadian Cardiovascular Society (CCS) anginal classification III or IV while receiving optimal medical therapy. Their treating cardiologist will have determined that they are generally not suitable for interventional therapy or bypass surgery.

"Developing a clinical trial protocol such as ours takes an extraordinary amount of time and effort, and I am pleased to finally open our Phase II heart trial for patient screening," said Daniel C. Montano, CVBT's President and CEO. "I expect additional investigators at other hospitals to begin screening patients in the coming weeks. Our target is 30 hospitals for this international Phase II heart trial."

About CardioVascular BioTherapeutics

CVBT (OTC Bulletin Board: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com.

For media inquiries please contact:

Allison Caplan, (702) 839-7200

acaplan@cvbt.com

For investor inquiries please contact:

Investor Relations, (702) 839-7220

investorrelations@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
2. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
10. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
11. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... -- This morning, Stock-Callers.com draws attention to ... at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... to develop technologies and products that combat debilitating and ... use less and cleaner energy, and provide safer, cleaner ...
(Date:1/13/2017)... -- The 2016 election resulted in a big ... in favor of legalizing cannabis for recreational use, including ... U.S. In addition, the state of Colorado ... sales. The ArcView Group has published an updated research report ... in the U.S. last year reached $6.7 billion, a growth of ...
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017 /PRNewswire-USNewswire/ ... type 1 diabetes (T1D) research, is pleased to ... advocacy efforts, the Centers for Medicare & Medicaid ... devices approved by the FDA for use in ... a significant step toward making them eligible for ...
Breaking Medicine Technology:
(Date:1/16/2017)... Louis, MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of ... here , This year’s influenza shot seems to be having no effect on ... area, at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... CITY, UT (PRWEB) , ... January 16, 2017 , ... ... disease not only to treat, but to test for, as well. The money spent ... billion every year.(1) Doctors in the U.S. screen patients for cancer more than in ...
(Date:1/15/2017)... York, NY (PRWEB) , ... January 15, 2017 , ... ... strategic accounts in the United States for the asthma & allergy friendly mark. This ... America to independently test and identify consumer products to be more suitable for the ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow ... ease," said Christina Austin - CEO of Pixel Film Studios. , On Tour’s ... the style and animation of their slideshows. Place each slide on top of another ...
(Date:1/15/2017)... ... January 15, 2017 , ... The ... is pleased to announce that it will be assisting HackensackUMC Mountainside with its ... Glen Ridge townships, servicing all surrounding towns. The firm will be working closely ...
Breaking Medicine News(10 mins):